ADAM17/TACE Protein, Human (CHO, His)
Based on 1 Customer Validation
The ADAM17/TACE protein cleaves TNF-α precursor, releasing its mature soluble form, and mediates the proteolytic release of JAM3 and various cell surface proteins, including p75 TNF receptor, type II IL1 receptor, TGF-α, L-selectin, growth hormone receptor, MUC1, and amyloid precursor protein. ADAM17/TACE Protein, Human (CHO, His) is the recombinant human-derived ADAM17/TACE protein, expressed by CHO , with C-His labeled tag.
- Species: Human
- Source: CHO
-
Storage:Stored at -80°C for 1 year from date of receipt. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Technical Parameters
-
Product Properties
- Documentation
- Help & FAQs
Biological Activity
Description
The ADAM17/TACE protein cleaves TNF-α precursor, releasing its mature soluble form, and mediates the proteolytic release of JAM3 and various cell surface proteins, including p75 TNF receptor, type II IL1 receptor, TGF-α, L-selectin, growth hormone receptor, MUC1, and amyloid precursor protein. ADAM17/TACE Protein, Human (CHO, His) is the recombinant human-derived ADAM17/TACE protein, expressed by CHO , with C-His labeled tag.
Background
The ADAM17/TACE protein functions as a pivotal protease involved in the cleavage of various membrane-bound precursor proteins, contributing to the regulation of diverse biological processes. Notably, ADAM17/TACE cleaves the membrane-bound precursor of TNF-alpha, releasing its mature soluble form, and is responsible for the proteolytic release of soluble JAM3 from endothelial cell surfaces. Additionally, it plays a critical role in the proteolytic release of several cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1, and the amyloid precursor protein. ADAM17/TACE serves as an activator of the Notch pathway by mediating the cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). Furthermore, it participates in the proteolytic processing of ACE2 and plays a role in hemostasis through the shedding of GP1BA, the platelet glycoprotein Ib alpha chain. ADAM17/TACE also mediates the proteolytic cleavage of LAG3 and IL6R, leading to the release of their secreted forms, and facilitates the shedding of FCGR3A upon NK cell stimulation, promoting increased NK cell motility and detachment from opsonized target cells.
Verified Bioactivity
Measured by its ability to cleave a fluorogenic peptide substrate Mca-PLAQAV-Dpa-RSSSR-NH2. The specific activity is >800 pmol/min/µg.
Technical Parameters
-
Species Human
-
Source CHO
-
Tag C-His
-
Accession
P78536 (R215-N671)
-
Gene ID6868
-
Molecular Construction
-
N-term
-
ADAM17 (R215-N671)
Accession # P78536 -
6*His
-
C-term
-
-
Protein Length
Extracellular Domain
-
Synonyms
ADAM17; Snake Venom-Like Protease; Prev. TACE; ADAM Metallopeptidase Domain 18; CSVP; Uncharacterized Protein ADAM17; Disintegrin And Metalloproteinase Domain-Containing Protein 17; TNF-Alpha Converting Enzyme; TNF-Alpha Convertase; CD156b Antigen; CD156B; ADAM17 Protein; Tumor Necrosis Factor, Alpha, Converting Enzyme; ADAM 17; A Disintegrin And Metalloproteinase 17; HYPT16; Cartilage Snake Venom-Like Protease; NISBD1; TNF-Alpha Convertase Enzyme; NISBD; TNF-Alpha-Converting Enzyme; ADAM Metallopeptidase Domain 17; ADAM18
-
AA Sequence
RADPDPMKNTCKLLVVADHRFYRYMGRGEESTTTNYLIELIDRVDDIYRNTSWDNAGFKGYGIQIEQIRILKSPQEVKPGEKHYNMAKSYPNEEKDAWDVKMLLEQFSFDIAEEASKVCLAHLFTYQDFDMGTLGLAYVGSPRANSHGGVCPKAYYSPVGKKNIYLNSGLTSTKNYGKTILTKEADLVTTHELGHNFGAEHDPDGLAECAPNEDQGGKYVMYPIAVSGDHENNKMFSNCSKQSIYKTIESKAQECFQERSNKVCGNSRVDEGEECDPGIMYLNNDTCCNSDCTLKEGVQCSDRNSPCCKNCQFETAQKKCQEAINATCKGVSYCTGNSSECPPPGNAEDDTVCLDLGKCKDGKCIPFCEREQQLESCACNETDNSCKVCCRDLSGRCVPYVDAEQKNLFLRKGKPCTVGFCDMNGKCEKRVQDVIERFWDFIDQLSINTFGKFLADN
-
Predicted Molecular Mass
53.1 kDa
-
Molecular Weight
Approximately 60-80 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.
-
Purity
≥ 80%, as determined by reducing SDS-PAGE.
Product Properties
Solution
Supplied as a 0.22 μm filtered solution of 20 mM Tris, 500 mM NaCl, pH7.5 with glycerol as protectant.
Note: For SPR assay, please replace the buffer. Primary amine components (e.g., Tris,
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O or PBS. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5%
Stored at -80°C for 1 year from date of receipt. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.
Shipping with dry ice.
Documentation
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz
